2021 World Conference on Lung Cancer (Posters)-FP01. Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC

FP01. Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC

Back to course

Video Transcription

Video Summary

The speaker presented data on real-world patients with EGFR-positive lung cancer at the World Lung Conference. The study aimed to estimate the prevalence, treatment patterns, and long-term outcomes of these patients. The prevalence of EGFR-positive patients was found to be 32%, with higher rates in females, never-smokers, and Asians. Disease-free survival was 29 months, with higher rates in stage 1b patients. Overall survival was not reached, but rates were similar for stage 2 and 3a patients. There was no significant difference in survival based on the type of EGFR mutation. The study concluded that patients with EGFR-positive lung cancer had similar outcomes to the placebo control arm of the ADORA trial.

Asset Subtitle

Sabine Schmid

Meta Tag

Speaker Sabine Schmid

Topic Early Stage/Localized Disease/Ablative Therapies

Keywords

EGFR-positive lung cancer

prevalence

treatment patterns

long-term outcomes

real-world patients